New gene therapy injection shows promise for tough leukemia
NCT ID NCT07246707
First seen Jan 11, 2026 · Last updated Jun 19, 2026 · Updated 28 times
Summary
This early-phase trial is testing a new gene therapy called KSV01 for patients with B-cell acute lymphoblastic leukemia that has come back or not responded to standard treatment. The study will enroll 30 adults aged 18 to 80 to check if the treatment is safe and tolerable, and to see if it can help control the disease. KSV01 uses a modified virus to deliver genetic instructions to the patient's own cells to fight the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-ALL are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
First Affiliated Hospital of Zhejiang University
RECRUITINGHangzhou, China
Contact Phone: •••-•••-••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
KSV01 injection (a gene therapy using a modified virus to target cancer cells)
What this could lead to
If successful, this could lead to a new treatment option for patients with hard-to-treat B-cell acute lymphoblastic leukemia.
What could go wrong
This is a very early phase 1 trial with only 30 people, so it's too soon to know if it works. There are risks like severe immune reactions or nerve problems.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.